Fig. 6From: A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer’s DiseaseEstimated APP production vs. Posiphen dose adjusted for pre-treatment CSF Aβ40Back to article page